Marksans Pharma is an Indian pharmaceutical company having a global footprint. Their strengths lie in research, manufacturing, and marketing of finished dosage pharmaceutical formulations. The company was incorporated in 1992 and is headquartered in Mumbai, India. Under the leadership of Mr. Mark Saldanha, the Chairman and Managing Director, Marksans Pharma has established itself as a global pharmaceutical company.
Marksans Pharmaceutical operates in more than 50 countries with over 1000 products. It has 7 fully owned subsidiaries in Germany, US, Russia, Philippines, Brazil, Canada, and Africa. The company has 815 total employees and operates two manufacturing facilities in Goa and maintains two R&D centers, one located in Goa and the other in Navi Mumbai.
Marksans Pharma is engaged in the business of formulation of pharmaceutical products. The company's product portfolio is strategically divided into two main segments that cater to different market needs and therapeutic areas.
* OTC Products: Constitute 74% of FY24 revenue and include Pain Management, Cough and Cold, Digestive Remedies, Vitamins and Tonics, Skin Treatments, and Allergies.
* Prescription (Rx) Products: Represent 26% of revenue and include cardiovascular, central nervous system (CNS), anti-allergic, anticancer, and anti-diabetic drugs.
The company has established world-class manufacturing facilities by leveraging state-of-the-art technology, incorporating best practices, and adhering to stringent regulatory compliances. Their plants are approved by prestigious US FDA, UK MHRA, Australian TGA, and other foreign health authorities.
Marksans Pharma's R&D capabilities include dossier development, chemical synthesis, process optimization, formulation development, analytical development, and conducting stability studies. The company has a team of over 50 experienced scientists specializing in formulation development and analytical development. They possess end-to-end capabilities – from Lab scale development to Pilot scale up and from commercializing the product for large scale manufacturing to marketing globally.
As of recent data, Marksans Pharma has a market capitalization of ₹11,803 Crore, representing a 39.9% increase over the past year, with revenue of ₹2,623 Crore and profit of ₹383 Crore. As of March 31, 2025, the company has a trailing 12-month revenue of $310 million.
The company has demonstrated strong financial performance in recent quarters. In Q1 FY25, Marksans Pharma reported significant revenue growth, posting INR 590.6 Crore, an 18.1% increase year-on-year, driven by new product launches and increased market share in the U.S., which saw a 29.8% revenue growth. Gross margins improved by 423 basis points to 55.7% due to lower raw material costs and a favorable product mix. The EBITDA margin rose to 21.7%.
Key financial metrics from recent quarters include:
* Q3 FY25: Operating revenue stood at ₹681.8 Crore, up by 16.3% YoY. Gross profit stood at ₹383.5 Crore, up by 22.4% YoY, with a gross margin expansion of 279 bps YoY to 56.2%.
* EBITDA stood at ₹138.8 Crore, up by 4.3% YoY, with a margin of 20.4%. EPS grew by 25.5% YoY to ₹2.3.
* Q1 FY25: Gross profit was ₹328.8 Crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%.
The company is a leader in the Cardiovascular segment and is the third in the industry in Gastro-Intestinal Drugs segment in the Indian market. Marksans Pharmaceuticals launched the world's first 'polypill' CVpill in Cardiac care and was also the first to launch India's first bulk laxative in tablet form (Fibotab).
In keeping with its mission towards global well-being, Marksans Pharma continues to enter into strategic partnerships with key players around the globe. These collaborative efforts help to deliver quality and timely pharmaceutical solutions across markets worldwide. Moving forward, the company believes in strengthening current partnerships while entering into new strategic alliances for innovative solutions in the ever-evolving healthcare sector.
The company has achieved several regulatory milestones recently. Marksans Pharma Limited's wholly-owned subsidiary Time-Cap Laboratories, Inc. received Establishment Inspection Report (EIR) from US Food & Drugs Administration for the audit conducted in October 2023. No 483's were issued during the Audit. The company's wholly-owned subsidiary Relonchem Limited received Marketing Authorisation for the product Cyanocobalamin 50mg film coated tablets from UK MHRA.
In June 2025, Marksans Pharma's subsidiary received USFDA Establishment Inspection Report post April 2025 inspection. The company's most recent deal was a Corporate Asset Purchase with Teva Pharm India (manufacturing Unit), which was completed on April 19, 2023.
The company has achieved global recognition within a very short span of time and has major global expansion plans for the near future. The company plans to stay within its current R&D expenditure range for at least the next two years, focusing on complex molecules that are expected to significantly enhance revenue streams in the long run.
According to Managing Director Mark Saldanha, the company is delighted to announce all-time high quarterly PAT, driven by robust growth, with revenue growth led by the US region, which witnessed 37% YoY growth, followed by UK, which improved during the quarter.
The company's strategic focus on expanding its global footprint, coupled with its strong R&D capabilities and regulatory compliance across multiple markets, positions it well for sustained growth in the competitive pharmaceutical industry.
